{"id":"https://openalex.org/W2771677620","doi":"https://doi.org/10.1111/apt.14466","title":"Comparison of infliximab with adalimumab in 827 biologic\u2010na\u00efve patients with Crohn's disease: a population\u2010based Danish cohort study","display_name":"Comparison of infliximab with adalimumab in 827 biologic\u2010na\u00efve patients with Crohn's disease: a population\u2010based Danish cohort study","publication_year":2017,"publication_date":"2017-12-14","ids":{"openalex":"https://openalex.org/W2771677620","doi":"https://doi.org/10.1111/apt.14466","mag":"2771677620","pmid":"https://pubmed.ncbi.nlm.nih.gov/29239001"},"language":"en","primary_location":{"id":"doi:10.1111/apt.14466","doi":"https://doi.org/10.1111/apt.14466","is_oa":false,"landing_page_url":"https://doi.org/10.1111/apt.14466","pdf_url":null,"source":{"id":"https://openalex.org/S158079644","display_name":"Alimentary Pharmacology & Therapeutics","issn_l":"0269-2813","issn":["0269-2813","1365-2036"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Alimentary Pharmacology & Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5035847062","display_name":"Siddharth Singh","orcid":"https://orcid.org/0000-0002-2640-7269","observed_orcids":["https://orcid.org/0000-0002-2640-7269","https://orcid.org/0000-0002-1388-6221"]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"S. Singh","raw_affiliation_strings":["Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA"],"raw_orcid":"https://orcid.org/0000-0002-2640-7269","affiliations":[{"raw_affiliation_string":"Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA","institution_ids":["https://openalex.org/I36258959"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047459850","display_name":"Nynne Nyboe Andersen","orcid":"https://orcid.org/0000-0003-0874-0356","observed_orcids":["https://orcid.org/0000-0003-0874-0356"]},"institutions":[{"id":"https://openalex.org/I101527212","display_name":"Statens Serum Institut","ror":"https://ror.org/0417ye583","country_code":"DK","type":"facility","lineage":["https://openalex.org/I101527212"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"N. N. Andersen","raw_affiliation_strings":["Department of Epidemiology Research, Statens Serum Institute, Copenhagen, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Epidemiology Research, Statens Serum Institute, Copenhagen, Denmark","institution_ids":["https://openalex.org/I101527212"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048615763","display_name":"Mikael Andersson","orcid":"https://orcid.org/0000-0002-0114-2057","observed_orcids":["https://orcid.org/0000-0002-0114-2057"]},"institutions":[{"id":"https://openalex.org/I101527212","display_name":"Statens Serum Institut","ror":"https://ror.org/0417ye583","country_code":"DK","type":"facility","lineage":["https://openalex.org/I101527212"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"M. Andersson","raw_affiliation_strings":["Department of Epidemiology Research, Statens Serum Institute, Copenhagen, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Epidemiology Research, Statens Serum Institute, Copenhagen, Denmark","institution_ids":["https://openalex.org/I101527212"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056735741","display_name":"Edward V. Loftus","orcid":"https://orcid.org/0000-0001-7199-6851","observed_orcids":["https://orcid.org/0000-0001-7199-6851"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"E. V. Loftus","raw_affiliation_strings":["Divison of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Divison of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5041209228","display_name":"Tine Jess","orcid":"https://orcid.org/0000-0002-4391-7332","observed_orcids":["https://orcid.org/0000-0002-4391-7332"]},"institutions":[{"id":"https://openalex.org/I101527212","display_name":"Statens Serum Institut","ror":"https://ror.org/0417ye583","country_code":"DK","type":"facility","lineage":["https://openalex.org/I101527212"]},{"id":"https://openalex.org/I2801150652","display_name":"Frederiksberg Hospital","ror":"https://ror.org/00d264c35","country_code":"DK","type":"healthcare","lineage":["https://openalex.org/I2801150652","https://openalex.org/I2802567020"]},{"id":"https://openalex.org/I2801941904","display_name":"Bispebjerg Hospital","ror":"https://ror.org/00td68a17","country_code":"DK","type":"healthcare","lineage":["https://openalex.org/I2801941904","https://openalex.org/I2802567020"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"T. Jess","raw_affiliation_strings":["Department of Epidemiology Research, Statens Serum Institute, Copenhagen, Denmark","Institute of Preventive Medicine, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark"],"raw_orcid":"https://orcid.org/0000-0002-4391-7332","affiliations":[{"raw_affiliation_string":"Department of Epidemiology Research, Statens Serum Institute, Copenhagen, Denmark","institution_ids":["https://openalex.org/I101527212"]},{"raw_affiliation_string":"Institute of Preventive Medicine, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark","institution_ids":["https://openalex.org/I2801150652","https://openalex.org/I2801941904"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5035847062"],"corresponding_institution_ids":["https://openalex.org/I36258959"],"apc_list":{"value":5250,"currency":"USD","value_usd":5250},"apc_paid":null,"fwci":1.9916,"has_fulltext":false,"cited_by_count":29,"citation_normalized_percentile":{"value":0.86720941,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":98},"biblio":{"volume":"47","issue":"5","first_page":"596","last_page":"604"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10134","display_name":"Inflammatory Bowel Disease","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10134","display_name":"Inflammatory Bowel Disease","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11194","display_name":"Ocular Diseases and Beh\u00e7et\u2019s Syndrome","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/crohn-s-disease","display_name":"Crohn's disease","score":0.9819999933242798},{"id":"https://openalex.org/keywords/infliximab","display_name":"infliximab","score":0.9879999756813049},{"id":"https://openalex.org/keywords/adalimumab","display_name":"adalimumab","score":1.0},{"id":"https://openalex.org/keywords/biologic-naive-patients","display_name":"biologic-naive patients","score":0.9160000085830688},{"id":"https://openalex.org/keywords/comparative-effectiveness","display_name":"comparative effectiveness","score":0.8930000066757202},{"id":"https://openalex.org/keywords/hospitalization","display_name":"hospitalization","score":0.6629999876022339},{"id":"https://openalex.org/keywords/abdominal-surgery","display_name":"abdominal surgery","score":0.871999979019165},{"id":"https://openalex.org/keywords/severe-infection","display_name":"serious infections","score":0.9900000095367432},{"id":"https://openalex.org/keywords/immunomodulators","display_name":"immunomodulators","score":0.7409999966621399},{"id":"https://openalex.org/keywords/tnf-alpha-inhibitors","display_name":"TNF-alpha inhibitors","score":0.6579999923706055},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.5899999737739563},{"id":"https://openalex.org/keywords/propensity-score-matching","display_name":"propensity score matching","score":0.9240000247955322},{"id":"https://openalex.org/keywords/first-line-biologic-therapy","display_name":"first-line biologic therapy","score":0.5680000185966492},{"id":"https://openalex.org/keywords/immunosuppression-risk","display_name":"immunosuppression risk","score":0.3970000147819519},{"id":"https://openalex.org/keywords/immunogenicity","display_name":"immunogenicity","score":0.35899999737739563},{"id":"https://openalex.org/keywords/health-care-utilization","display_name":"health care utilization","score":0.6299999952316284}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9510769844055176},{"id":"https://openalex.org/C2777138892","wikidata":"https://www.wikidata.org/wiki/Q415264","display_name":"Infliximab","level":3,"score":0.9194403886795044},{"id":"https://openalex.org/C2780132546","wikidata":"https://www.wikidata.org/wiki/Q348260","display_name":"Adalimumab","level":3,"score":0.8931357860565186},{"id":"https://openalex.org/C17923572","wikidata":"https://www.wikidata.org/wiki/Q7250160","display_name":"Propensity score matching","level":2,"score":0.7846727967262268},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.7139148712158203},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6702498197555542},{"id":"https://openalex.org/C2779280984","wikidata":"https://www.wikidata.org/wiki/Q1472","display_name":"Crohn's disease","level":3,"score":0.4949495196342468},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.48419907689094543},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.47323712706565857},{"id":"https://openalex.org/C201903717","wikidata":"https://www.wikidata.org/wiki/Q1778788","display_name":"Cohort study","level":2,"score":0.45396339893341064},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.44735419750213623},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.37258124351501465},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.2755689024925232},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.1906917691230774},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000068879","descriptor_name":"Adalimumab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000069285","descriptor_name":"Infliximab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001688","descriptor_name":"Biological Products","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D003424","descriptor_name":"Crohn Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003424","descriptor_name":"Crohn Disease","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D003718","descriptor_name":"Denmark","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007155","descriptor_name":"Immunologic Factors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012042","descriptor_name":"Registries","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014409","descriptor_name":"Tumor Necrosis Factor-alpha","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D015331","descriptor_name":"Cohort Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1111/apt.14466","doi":"https://doi.org/10.1111/apt.14466","is_oa":false,"landing_page_url":"https://doi.org/10.1111/apt.14466","pdf_url":null,"source":{"id":"https://openalex.org/S158079644","display_name":"Alimentary Pharmacology & Therapeutics","issn_l":"0269-2813","issn":["0269-2813","1365-2036"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Alimentary Pharmacology & Therapeutics","raw_type":"journal-article"},{"id":"pmid:29239001","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/29239001","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Alimentary pharmacology & therapeutics","raw_type":"Comparative Study"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320306301","display_name":"Crohn's and Colitis Foundation of America","ror":"https://ror.org/05f2xbq60"},{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320310104","display_name":"American College of Gastroenterology","ror":"https://ror.org/04cheq228"},{"id":"https://openalex.org/F4320318316","display_name":"Celltrion","ror":"https://ror.org/05k84m754"},{"id":"https://openalex.org/F4320337449","display_name":"Janssen Biotech","ror":"https://ror.org/03qd7mz70"},{"id":"https://openalex.org/F4320337846","display_name":"UCB Pharma","ror":"https://ror.org/01n029866"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":30,"referenced_works":["https://openalex.org/W1124229","https://openalex.org/W1519803364","https://openalex.org/W1521836421","https://openalex.org/W1878621938","https://openalex.org/W1979434114","https://openalex.org/W1995803004","https://openalex.org/W2000183493","https://openalex.org/W2013592287","https://openalex.org/W2019062711","https://openalex.org/W2023610910","https://openalex.org/W2056917411","https://openalex.org/W2070315801","https://openalex.org/W2096675088","https://openalex.org/W2104847223","https://openalex.org/W2120539905","https://openalex.org/W2122527047","https://openalex.org/W2125693233","https://openalex.org/W2126807394","https://openalex.org/W2129168200","https://openalex.org/W2143747121","https://openalex.org/W2148567965","https://openalex.org/W2301869456","https://openalex.org/W2335895559","https://openalex.org/W2404971681","https://openalex.org/W2418156720","https://openalex.org/W2507736693","https://openalex.org/W2525802576","https://openalex.org/W2557758648","https://openalex.org/W2741466972","https://openalex.org/W4295333203"],"related_works":["https://openalex.org/W4383058287","https://openalex.org/W4246363283","https://openalex.org/W3172200283","https://openalex.org/W2999078475","https://openalex.org/W3080888293","https://openalex.org/W2557758648","https://openalex.org/W2773742325","https://openalex.org/W2894877589","https://openalex.org/W2033239527","https://openalex.org/W2096675088"],"abstract_inverted_index":{"BACKGROUND:":[0],"There":[1,189],"are":[2],"conflicting":[3],"data":[4],"on":[5],"comparative":[6],"effectiveness":[7,22,268],"of":[8,25,47,73,99,154,178,196,271],"adalimumab":[9,26,57,272],"and":[10,23,27,81,97,116,173,269,273],"infliximab":[11,28,59,274],"in":[12,29,34,42,152,183,194,208,230,267,275],"patients":[13,31,185,209,277],"with":[14,32,51,56,126,211,232,278],"Crohn's":[15],"disease":[16,93,128],"(CD).":[17],"AIMS:":[18],"To":[19],"compare":[20],"the":[21],"safety":[24,270],"biologic-na\u00efve":[30,276],"CD,":[33],"a":[35,138],"nationwide":[36],"register-based":[37],"propensity":[38,87,253],"score-matched":[39],"cohort":[40,257],"study":[41,258],"Denmark.":[43],"METHODS:":[44],"A":[45],"total":[46],"2908":[48],"Danish":[49],"adults":[50],"CD":[52],"had":[53,133],"been":[54],"treated":[55,210],"or":[58,164,229],"as":[60],"their":[61],"first":[62],"biologic":[63],"agent":[64],"between":[65,171],"2005-2014.":[66],"By":[67],"Cox":[68],"regression,":[69],"we":[70,106],"compared":[71],"rates":[72],"all-cause":[74,179],"hospitalisation,":[75,77],"CD-related":[76,100,155,219,239],"major":[78,165],"abdominal":[79,135,166,224,244],"surgery":[80,167],"serious":[82,197],"infections":[83,198],"after":[84,143],"variable":[85],"2:1":[86],"score":[88,254],"matching,":[89,105],"accounting":[90],"for":[91],"baseline":[92],"characteristics,":[94],"healthcare":[95],"utilisation":[96],"use":[98],"medications.":[101],"RESULTS:":[102],"After":[103],"propensity-score":[104],"included":[107],"315":[108],"adalimumab-":[109,172],"(34.9":[110],"\u00b1":[111,120],"12.9":[112],"years,":[113,122],"41.9%":[114],"males)":[115,124],"512":[117],"infliximab-treated":[118,174],"(33.6":[119],"12.6":[121],"40.8%":[123],"patients,":[125,175],"median":[127,139],"duration":[129],"4.0":[130],"years;":[131],"36.9%":[132],"prior":[134],"surgery.":[136],"Over":[137],"follow-up":[140],"2.3":[141],"years":[142],"starting":[144],"biological":[145,212],"therapy,":[146],"there":[147,262],"were":[148,206],"no":[149,191,264],"significant":[150,192,265],"differences":[151],"rate":[153,177],"hospitalisation":[156,180,200],"(hazard":[157],"ratio":[158],"[HR],":[159],"0.81":[160],"[95%":[161],"CI,":[162],"0.55-1.20])":[163],"(HR,":[168,186,201],"1.24":[169],"[0.66-2.33])":[170],"though":[176],"was":[181,190,263],"lower":[182],"adalimumab-treated":[184],"0.74":[187],"[0.56-0.97]).":[188],"difference":[193,266],"incidence":[195],"requiring":[199],"1.06":[202],"[0.26-4.21]).":[203],"These":[204],"results":[205],"stable":[207],"monotherapy":[213],"(all-cause":[214,234],"hospitalisation:":[215,220,235,240],"HR,":[216,221,226,236,241,246],"0.75":[217],"[0.53-1.05];":[218],"0.82":[222],"[0.51-1.32],":[223],"surgery:":[225,245],"1.47":[227],"[0.63-3.47])":[228],"combination":[231],"immunomodulators":[233],"0.70":[237],"[0.44-1.11];":[238],"0.80":[242],"[0.42-1.52],":[243],"1.02":[247],"[0.39-2.64]).":[248],"CONCLUSIONS:":[249],"In":[250],"this":[251],"population-based,":[252],"matched,":[255],"real-life":[256],"using":[259],"administrative":[260],"claims,":[261],"CD.":[279]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":6},{"year":2018,"cited_by_count":3}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2017-12-22T00:00:00"}